Tendon pathology in hypercholesterolaemia patients: Epidemiology, pathogenesis and management

Yang Yang a, Hongbin Lu b, Jin Qu b,*

a Department of Cardiovascular Disease, The Second Xiangya Hospital, Central South University, Changsha 410011, PR China
b Department of Sports Medicine, Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Xiangya Hospital, Central South University, Changsha 410008, PR China

Received 13 May 2018; received in revised form 4 July 2018; accepted 12 July 2018
Available online 6 August 2018

Abstract

Tendon pathology is a general term used to describe a group of musculoskeletal conditions related to tendons and surrounding structures. There is only limited evidence available regarding the exact aetiology and natural history of tendon pathology. In hypercholesterolaemia environments, lipids could accumulate within the extracellular matrix of the tendon and thus affect the mechanical properties of the tendon. Current evidence suggested that hypercholesterolaemia was an important risk factor in the development and progression of tendon pathology. The severity of hypercholesterolaemia was correlated with the severity of tendon pathology.

The translational potential of this article: Hypercholesterolaemia lead to the structural, inflammatory and mechanical changes in tendons, which predispose hypercholesterolaemia patients to a greater risk of tendon pathology. Measurements of serum cholesterol are suggested to be performed in patients presenting with tendon pathology. The strict control of hypercholesterolaemia would mitigate the development and progression of tendon pathology.

© 2018 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Background

Tendon pathology is a general term used to describe a group of musculoskeletal conditions related to tendons and surrounding structures [1]. Tendon pathology could be broadly classified into traumatic, degenerative and...
overuse-related tendinopathy. Rotator cuff tears, Achilles tendinopathy, Achilles tendon rupture, and tennis elbow are common examples of these conditions. Tendon xanthoma is a special type of tendon pathology. There is only limited evidence available regarding the exact aetiology and natural history of tendon pathology [2]. Possible etiologic factors may include aging, overuse, trauma, biomechanical abnormalities, glucocorticoids use, quinolone antibiotics use, microcirculation, and metabolic disorders [3]. Because the pathogenesis of tendon pathology is so complex and involves a variety of biological phenomena, there is no consistently effective treatment available for tendon pathology. Clinically available treatment options may include nonsteroid antiinflammatory drug, corticosteroid injection, platelet-rich plasma injection, low-energy laser stimulation, extracorporeal shock wave therapy, and surgical interventions [3]. Although these approaches may relieve the symptoms in the short term, there is presently limited scientific evidence supporting these therapies and their efficacy.

Hypercholesterolaemia is a systemic metabolic disease characterised by abnormally high levels of cholesterol in the blood. Hypercholesterolaemia is defined as elevated amounts of total cholesterol ($\geq$240 mg/dL) in the blood. Hypercholesterolaemia has well-known impact on vascular systems and internal organs [4]. Recently, the influence of hypercholesterolaemia on musculoskeletal system has attracted much attention. In hypercholesterolaemia environments, lipids could accumulate within the extracellular matrix of the tendon and thus affect the mechanical properties of the tendon [5,6]. Several studies have explored the relationship between hypercholesterolaemia and tendon pathology. Animal studies indicated that high levels of cholesterol would lead to poorer mechanical properties and adversely affect tendon healing after surgical repair [7–9], while clinical studies showed inconsistent results on the association between hypercholesterolaemia and tendon pathology [10,11]. Better understanding of the relationship between hypercholesterolaemia and tendon pathology, the impact of hypercholesterolaemia on tendon structure and healing as well as the mechanisms of hypercholesterolaemia in the development and progression of tendon pathology would aid the development of an effective treatment strategy.

The purpose of this review was (1) to summarise the association between hypercholesterolaemia and tendon pathology, (2) to discuss the pathogenic mechanisms in causing and exacerbating tendon pathology and (3) to explore the potential treatment strategies for tendon pathology in hypercholesterolaemia patients.

### Epidemiology of tendon pathology in hypercholesterolaemia patients

The association between hypercholesterolaemia and tendon pathology was reviewed by searching the original research articles in PubMed. The search algorithm was “(tendon or tendinopathy) AND (hyperlipidaemia or dyslipidaemia or hypercholesterolaemia or statin)”. There was significant heterogeneity among the included studies on study design, participants, grouping, sample size and statistical methods. Hypercholesterolaemia is defined as elevated amounts of total cholesterol ($\geq$240 mg/dL) in the blood. The causes of hypercholesterolaemia include diet, lifestyle and genetics [12]. Based on the family history and genetics, hypercholesterolaemia could be divided into familial hypercholesterolaemia (FH) and nonfamilial hypercholesterolaemia (non-FH) [12]. The epidemiology of tendon pathology at FH and non-FH patients was summarised below.

### Hypercholesterolaemia and tendon pathology in patients with FH

FH is an inherited genetic disorder, characterised by obviously elevated levels of low-density lipoprotein (LDL) cholesterol, xanthomas and family history of premature atherosclerosis. Based on the family history, FH could be classified as homozygous and heterozygous. The homozygous FH has a prevalence of one per million [13], whereas heterozygous FH affects about one in 200–600 people [14]. Tendon xanthomas are cholesterol deposits within certain tendons, commonly on the Achilles tendons and extensor tendons of the hands [15]. Tendon xanthomas usually appeared in homozygous FH since childhood, while it started to develop after the age of 20 years in patients with heterozygous FH [16]. Approximately 20%–80% of FH patients with genetic diagnosis have tendon xanthomas [17]. It is unknown why some FH patients develop tendon xanthomas and others do not, even with the similar genetic factors. Furthermore, FH could present as Achilles tendinopathy before the development of tendon xanthomas [18]. Measurement of serum cholesterol in patients presenting with painful Achilles tendon could lead to early diagnosis of FH.

### Hypercholesterolaemia and tendon pathology in patients without FH

Overuse is considered a major causative factor for tendinopathy. However, a large portion of cases occurred among completely nonactive individuals [19]. People with high body mass index are more likely to suffer from tendinopathy [20]. Though overweight directly affects tendon loading, it is unlikely that increased tendon loading adequately explains these relationships [21]. Alternate mechanisms linking obesity and tendinopathy may be high prevalence of metabolic disorders in the obesity.

Hypercholesterolaemia has been implicated as a risk factor for tendon pathology, but the evidence is mixed. Currently, 15 clinical studies explored the relationship between hyperlipidaemia and tendon pathology. Ten of 15 studies demonstrated that there was an association between dyslipidaemia and tendon pathology (Summarised in Table 1). Gaida et al [22] compared the serum lipid profile between participants with Achilles tendinopathy and those without Achilles tendinopathy and indicated that Achilles tendinopathy was associated with dyslipidaemia and the metabolic syndrome. Abboud et al [23] prospectively collected serum cholesterol and lipid profiles in patients with or without rotator cuff tears and indicated that patients with rotator cuff tears were more likely to have
| First author | Year | Design | Participants | Sample size | Primary findings | Association |
|--------------|------|--------|--------------|-------------|------------------|-------------|
| Mathiak [57] | 1999 | Case series | Patients with surgical treatment of Achilles tendon ruptures | Total: 41 | Cholesterol levels were found to be elevated in 83% of patients | Yes |
| Ozgurtas [58] | 2003 | Retrospective cohort study | Study group: with complete ruptures of Achilles tendon | Study group: 47; Control group: 26 | Total cholesterol and low-density lipoprotein cholesterol concentrations of the patients with ATR were higher, and their high-density lipoprotein cholesterol was lower than the control group. | Yes |
| Gaida [22] | 2009 | Prospective cohort study | Study group: with chronic painful midportion Achilles tendinopathy; Control group: without a history of tendon injury | Study group: 60; Control group: 60 | Higher triglyceride levels, lower 5% HDL-C, higher TG/HDL-C ratio, and elevated apolipoprotein B concentration. | Yes |
| Abboud [23] | 2010 | Prospective cohort study | Study group: with rotator cuff tears; Control group: with shoulder pain but without tears | Study group: 74; Control group: 73 | Total cholesterol, TG, and LDL-C concentrations of the patients with rotator cuff tendon tears were significantly higher than the control group. The high-density lipoprotein cholesterol showed a trend to being lower than the control group. | Yes |
| Longo [11] | 2010 | Case–control study | Study group: arthroscopic repair of a rotator cuff tear; Control group: arthroscopic meniscectomy for a meniscal tear | Study group: 120; Control group: 120 | There was no statistically significant difference in serum TG and TC concentration. | No |
| Rechardt [59] | 2013 | Cross-sectional study | Patients with incipient upper extremity pain with symptom duration of less than 1 month | Total: 163 | Obesity, high-density lipoprotein cholesterol and triglycerides were associated with pain intensity. | Yes |
| Abate [60] | 2014 | Cross-sectional study | Group 1: female patient with lower limb diseases older than 44 years and with regular menstrual cycles; Group 2: postmenopause 2–7 years | Group 1: 110; Group 2: 122 | High TG and low HDL-C were associated with an increased risk of asymptomatic rotator cuff tears. This was not statistically significant with TC. | Yes |
| Oliva [61] | 2014 | Retrospective observational study | Patients with nontraumatic rotator cuff tear | Total: 441 | High proportions of patients with nontraumatic rotator cuff tears had hypercholesterolaemia. High portions of patients with hypercholesterolaemia took cholesterol-lowering medications. | Yes |
| Djerbi [62] | 2015 | Prospective cohort study | Study group: patients undergoing arthroscopic rotator cuff repair; Control group: operated on other parts but not shoulder | Study group: 206; Control group: 100 | Patients with dyslipidaemia had significantly higher odds ratio of rotator cuff tears. | Yes |
hypercholesterolaemia. Lin et al [10] explored the effect of hyperlipidaemia on the development of rotator cuff disease and demonstrated that hyperlipidaemia was an independent risk factor for rotator cuff disease development. An increased risk also existed in patients with hyperlipidaemia with/without statin use. Statin use was associated with a lower risk of developing rotator cuff diseases when compared with no statin use.

For FH patients, hypercholesterolaemia is associated with xanthoma formation. While for non-FH patients, there is a potential role of hypercholesterolaemia in predisposing to tendon pathology in the general population. It looks like

| First author | Year | Design | Participants | Sample size | Primary findings | Association |
|--------------|------|--------|--------------|-------------|-----------------|-------------|
| Lin [10]     | 2015 | Retrospective cohort study | Randomly selected from national health research database | Total: 498678 | Hyperlipidaemia was an independent risk factor for rotator cuff disease development. An increased risk also existed in patients with hyperlipidaemia with/without statin use. Statin use was associated with a lower risk of developing rotator cuff diseases when compared with no statin use. | Yes |
| Davis [24]   | 2016 | Prospective cohort study | Study group: rotator cuff tear requiring a repair Control group: with intact rotator cuff | Study group: 40 Control group: 37 | There were no significant differences in any lipid values between patients with rotator cuff and those without a tear. Rotator cuff tears were more frequent in the hyperlipidaemia group although statistical analysis showed no significant difference. Patients with hyperlipidaemia had significantly less improvement in pain level. | No |
| Kim [63]     | 2016 | Retrospective cohort study, | Study group: supraspinatus tendinopathy with dyslipidaemia Control group: supraspinatus tendinopathy without dyslipidaemia | Study group: 49 Control group: 50 | | Yes |
| Abate [64]   | 2017 | Case series | Group 1: with monolateral rotator cuff tear Group 2: with bilateral rotator cuff tear | Group 1: 111 Group 2: 69 | There was no association of bilateral rotator cuff tears with hypercholesterolaemia and statin therapy. Hypercholesterolaemia was statistically associated with glenohumeral joint pain, but not rotator cuff tendinopathy. | No |
| Applegate [65] | 2017 | Cross-sectional study | Workers were recruited from 17 diverse production facilities | Total: 1226 | Hypercholesterolaemia was statistically associated with glenohumeral joint pain, but not rotator cuff tendinopathy. There were no significant difference in the rate of dyslipidaemia between rotator cuff–related osteoarthritis and primary shoulder osteoarthritis. | No |
| Juge [66]    | 2017 | Retrospective cohort study | Group 1: with rotator cuff–related osteoarthritis Group 2: with primary shoulder osteoarthritis | Group 1: 48 Group 2: 99 | | No |

LDL-C = low-density lipoprotein cholesterol; ATR = Achilles tendon ruptures; HDL-C = high-density lipoprotein cholesterol; TG = triglyceride; TC = Total cholesterol.
that people with worse hypercholesterolaemia (as FH) are more likely to suffer from tendon pathology, even tendon xanthomas.

**Pathogenic mechanisms**

Extracellular matrix remodelling and inflammation are reported to be two key factors in the development of atherosclerosis in hypercholesterolaemia patients [25]. There is limited evidence regarding the potential pathogenic mechanisms of hypercholesterolaemia on tendon. It is necessary to summarise the current evidence of the mechanisms of lipid deposition in tendon. Furthermore, the pathogenic mechanisms of hypercholesterolaemia on tendon were summarised from the following three points: inflammation, tendon structural changes and changes in mechanical properties (Figure 1).

**The mechanisms of lipid deposition in tendon**

The direct impact of hypercholesterolaemia on tendon is cholesterol deposits within tendon tissues, along with the changes of tendon mechanical properties [7,15]. Tendon xanthomas are usually accompanied by an increase in tendon size, correlated with the degree of hypercholesterolaemia [26]. The main constituents of tendon xanthomas are lipids and collagen. In tendon xanthomas, Kruth [15] indicated that unesterified cholesterol accumulated predominantly extracellularly in the tendon as human atherosclerotic lesions, while esterified cholesterol and triglyceride accumulated both extracellularly and intracellularly. Lipid analysis of tendon xanthomas indicated that the lipid was composed of 55% free cholesterol, 28% cholesterol esters and 13% phospholipids [27,28]. Bhattacharyya et al [29] explored the turnover of xanthoma cholesterol in hypercholesterolaemia patients and suggested total exchangeability of cholesterol between plasma and xanthomas. Accordingly, lipids in tendon xanthomas are more likely to be derived from the circulation rather than from local synthesis, secretion or cell death. These findings were supported by the study of Armstrong et al [30] indicating active uptake of LDL by the lesions within xanthomas. Sugiyama et al [31] determined the presence and distribution of lipoproteins by immunohistochemical methods and indicated that oxidatively modified low-density lipoprotein (oxLDL) appeared to have a similar distribution in xanthoma to that of macrophages. Furthermore, the study demonstrated that oxLDL was associated with macrophages and occurred intracellularly. LDL was detected extracellularly, with a distribution that was different from that of oxLDL [31]. It was assumed that LDL derived from plasma was trapped in the tendon matrix and oxidised by macrophages or other cells. The majority of the xanthoma cells were considered to be derived from macrophages after taking up oxLDL.

**Inflammation in the pathological process of tendon pathology**

The role of inflammation in the development and progression of cardiovascular diseases is well established. Thus, inflammation is suggested to be the main pathological mechanism of tendon pathology in hypercholesterolaemia patients. Artieda et al [32] indicated that macrophages derived from patients with tendon xanthomas were more likely to form foam cells than macrophages from patients without tendon xanthomas. FH patients with tendon xanthomas showed increased serum tryptase, tumour necrosis factor-α, interleukin-8, and interleukin-6 concentrations than FH patients without tendon xanthomas. These authors proposed that tendon xanthomas formation was associated with
higher intracellular lipid content and higher inflammatory response of macrophages. In addition, Oosterveer et al [33] indicated that variants in the ALOX5AP (5-lipoxygenase activating protein) gene were associated with the presence of tendon xanthomas in FH patients. ALOX5AP is involved in the biosynthesis of leukotrienes by mediating the activity of 5-lipoxygenase. Leukotrienes promote leucocyte chemotaxis and increase vascular permeability. The authors concluded that inflammation was a pathogenic factor of tendon xanthomas. CXCL3 is a chemokine belonging to the growth-regulated oncogene family, which acts as mediators in allergy, inflammation and immunity. The study by Martin-Fuentes et al [34] indicated that chemokines belonging to the CXC family could play an important role in the aetiology of tendon xanthomas. CXCL3 was a possible biological marker of onset and development of tendon xanthomas. Hjuler Nielsen et al [35] concluded that lipoprotein-associated oxidative stress was involved in tendon xanthomas by inducing proinflammatory monocytes and increased release of MMPs. These above studies consistently showed that inflammation was involved in the development of tendon xanthomas.

Tendon structural changes in hypercholesterolaemia environment

Hypercholesterolaemia environment would alter tendon homoeostasis. Hypercholesterolaemia was associated with decreased synthesis of noncollagenous proteins and decreased incorporation of extracellular matrix components [36]. Nakano et al [37] explored the pathogenesis of tendon xanthomas in rabbits and showed that a large number of blood vessels were seen in the xanthomas tissues. Immunohistochemical evaluation revealed that the xanthoma plaques contained endothelial cells and macrophages. Nunes et al [38] investigated the effects of hypercholesterolaemia on the collagen composition of urinary bladder wall and indicated that hypercholesterolaemia induced morphological alterations of collagen fibres and the amounts of type III collagen. Oberekisch et al showed that hypercholesterolaemia affected proteoglycans synthesis [39]. In summary, current evidence suggested that hypercholesterolaemia could alter the tendon microenvironment via local changes in protein synthesis and extracellular matrix remodelling.

Changes in mechanical properties of tendon in hypercholesterolaemia environment

Hypercholesterolaemia could affect the mechanical strength of plaques by inducing local collagen loss and render atherosclerotic plaques prone to rupture [40]. The effects of hypercholesterolaemia on biomechanical properties of tendon have been explored in animal models. Hypercholesterolaemia is believed to contribute to increased tendon injury in several ways. Beason et al [7] explored the effect of high cholesterol on tendon properties in mice and indicated that there was a detrimental effect of hypercholesterolaemia on tendon properties. In addition, another study by Beason et al [8] explored the effect of hypercholesterolaemia on supraspinatus tendon elastic mechanical properties in mice, rats and monkeys. The authors concluded that hypercholesterolaemia could lead to an increase in stiffness and elastic modulus of the supraspinatus tendons in these species. Hypercholesterolaemia-related changes on mechanical properties might lead to the increased rates of tendon injury. Chung et al [41] explored the effect of hyperlipidaemia on fatty infiltration and tendon-to-bone healing in a rabbit model and demonstrated that hyperlipidaemia had a deleterious effect on fatty infiltration and tendon-to-bone healing. Hypercholesterolaemia could alter the biomechanical properties of tendon and thus render tendon prone to injury.

Managements for tendon pathology in hypercholesterolaemia patients

The best approach towards tendon pathology in patients with hypercholesterolaemia is treating the metabolic disorder of lipid metabolism. When lifestyle changes are not effective in lowering the serum cholesterol, statins are recommended for the first-line treatment. Statins are the most widely prescribed medications to treat hyperlipidaemia and reduce the risk of cardiovascular diseases and related mortality [42,43]. Several studies have demonstrated that statins are effective in decreasing the size of tendon xanthomas [44,45]. Statins work by lowering serum cholesterol and are therefore associated with mobilisation of cholesterol from tendon xanthomas. In the patients without FH, use of statins is associated with a lower risk of developing tendon pathology when compared with no statin use [10]. However, statins are known to have a potentially deleterious effect on muscle. Use of statins was associated with myalgia, muscle injury, increase in creatine kinase and even rarer rhabdomyolysis [46]. In addition, several studies suggested that use of statins might be associated with tendon pathology and tendon ruptures [47,48]. Thus, the benefits of statins on tendon pathology needed to be balanced with the potential adverse effects on tendon.

The goal of cholesterol reduction in patients with FH is minimal reduction ≥50% of LDL cholesterol or at ideal LDL cholesterol level [14]. When high-dose statins are not effective in lowering the serum cholesterol, second-line drugs such as ezetimibe, PCSK9 inhibitors, niacin or bile acid sequestrants should be added to further decrease the cholesterol levels [14]. The combination of statins and ezetimibe decreases both the production of cholesterol in the liver and absorption of dietary cholesterol in small intestine [49]. Adding PCSK9 inhibitor should be considered if the ideal goal of cholesterol reduction could not be reached after treatment with high-dose statins plus ezetimibe [50]. Bile acid sequestrants and niacin are optional depending on the availability, toxic effects, and costs. Other approaches including lomitapide, mipomersen, lipoprotein apheresis and liver transplantation are not commonly prescribed and could be considered when the above triple-drug therapies (statins, ezetimibe and PCSK9 inhibitor) are not effective [14]. Finally, surgical resection of the tendon xanthomas might be considered in some severe cases [51].

Besides control of hypercholesterolaemia, several approaches were suggested to promote tendon regeneration after removing primary diseases. Popular injectable
substances included growth factors, platelet-rich plasma, autologous blood, mesenchymal stem cells, stromal vascular fraction and bone marrow aspirate concentrate. A meta-analysis of controlled studies has shown that platelet-rich plasma is a safe and promising therapy in the treatment of recalcitrant patellar tendinopathy [52]. Another study indicated that platelet-rich plasma could ameliorate the pain of tendinopathy in the intermediate—long term compared with the control interventions [53]. A recent pilot study revealed that there was a therapeutic value of mesenchymal stem cell injection for treating chronic tendinopathy [54]. Usuelli et al [55] indicated that intratendinous adipose-derived stromal vascular fraction injection provided a safe and efficacious treatment for Achilles tendinopathy. A recent study systematically reviewed the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology [56]. The authors concluded that there were only limited clinical studies available and future randomised controlled studies were highly needed.

Conclusion

Current evidence generally suggested that hypercholesterolaemia was an important risk factor in the development and progression of tendon pathology. The severity of hypercholesterolaemia was correlated with the severity of tendon pathology. Hypercholesterolaemia lead to the structural, inflammatory and mechanical changes in tendons, which predispose hypercholesterolaemia patients to a greater risk of tendon pathology. The strict control of hypercholesterolaemia would mitigate the development and progression of tendon pathology.

Conflict of interest statement

The authors have no conflicts of interest relevant to this article.

Funding/Acknowledgement

This study was funded by the National Natural Science Foundation of China (81500358 and 81501898).

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jot.2018.07.003.

References

[1] Abate M, Silbernagel KG, Siljeholm C, Di Iorio A, De Amicis D, Salini V, et al. Pathogenesis of tendinopathies: inflammation or degeneration? Arthritis Res Ther 2009;11:235.
[2] Kaou JF, Forthomme B, Goff CL, Crielael JM, Croisier JL. Current opinions on tendinopathy. J Sports Sci Med 2011;10:238–53.
[3] Li HY, Hua YH. Achilles tendinopathy: current concepts about the basic science and clinical treatments. Biomed Res Int 2016;2016:6492597.
[4] Duan S, Zhang Y, Wu SJ, Jiang LZ, Zhang J, Gan Y, et al. Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits. Exp Lung Res 2010;36:573–92.
[5] Soslowsky LJ, Fryhofer GW. Tendon homeostasis in hypercholesterolemia. Adv Exp Med Biol 2016;920:151–65.
[6] Taylor B, Cheema A, Soslowsky L. Tendon pathology in hypercholesterolemia and familial hypercholesterolemia. Curr Rheumat Rep 2017;19:76.
[7] Beason DP, Abboud JA, Kuntz AF, Bassora R, Soslowsky LJ. Cumulative effects of hypercholesterolemia on tendon biomechanics in a mouse model. J Orthop Res 2011;29:380–3.
[8] Beason DP, Hsu JE, Marshall SM, McDaniel AL, Temel RE, Abboud JA, et al. Hypercholesterolemia increases supraspinatus tendon stiffness and elastic modulus across multiple species. J Shoulder Elbow Surg 2013;22:681–6.
[9] Beason DP, Tucker JJ, Lee CS, Edelstein L, Abboud JA, Soslowsky LJ. Rat rotator cuff tendon-to-bone healing properties are adversely affected by hypercholesterolemia. J Shoulder Elbow Surg 2014;23:867–72.
[10] Lin TT, Lin CH, Chang CL, Chi CH, Chang ST, Sheu WH. The effect of diabetes, hyperlipidemia, and statins on the development of rotator cuff disease: a nationwide, 11-year, longitudinal, population-based follow-up study. Am J Sports Med 2015;43:2126–32.
[11] Longo UG, Franceschi F, Spiezia F, Forrilo F, Maffulli N, Denaro V. Triglycerides and total serum cholesterol in rotator cuff tears: do they matter? Br J Sports Med 2010;44:948–51.
[12] Xiang R, Fan LL, Lin MJ, Li JJ, Shi XY, Jin JY, et al. The genetic spectrum of familial hypercholesterolemia in the central south region of China. Atherosclerosis 2017;258:84–8.
[13] Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012;223:262–8.
[14] Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016;4:850–61.
[15] Kruth HS. Lipid deposition in human tendon xanthoma. Am J Pathol 1985;121:311–5.
[16] Pejic RN. Familial hypercholesterolaemia. Ochsner J 2014;14:669–72.
[17] Oosterveer DM, Versmissen J, Yazdanpanah M, Hamza TH, Sijbrands EJ. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis 2009;207:311–7.
[18] Beeharry D, Coupe B, Benbow EW, Morgan J, Kwok S, Charlton-Menys V, et al. Familial hypercholesterolemia commonly presents with Achilles tendosynovitis. Ann Rheum Dis 2006;65:312–5.
[19] Rolf C, Movin T. Histopathology, and outcome of surgery in achillodynia. Foot Ankle Int 1997;18:565–9.
[20] Franceschi F, Papalia R, Paciotti M, Franceschetti E, Di Martino A, Maffulli N, et al. Obesity as a risk factor for tendinopathy: a systematic review. Int J Endocrinol 2014;2014:670262.
[21] Gaida JE, Cook JL, Bass SL. Adiposity and tendinopathy. Disabil Rehabil 2008;30:1555–62.
[22] Gaida JE, Alfredson L, Kiss ZS, Wilson AM, Alfredson H, Cook JL. Dyslipidemia in Achilles tendinopathy is characteristic of insulin resistance. Med Sci Sports Exerc 2009;41:1194–7.
[23] Abboud JA, Kim JS. The effect of hypercholesterolemia on rotator cuff disease. Clin Orthop Relat Res 2010;468:1493–7.
[24] Davis DE, Narzikul A, Sholder D, Lazarus M, Namdari S, Abboud J. Shoulder synovial fluid lipoprotein levels and their
relationship to the rotator cuff. Med Sci Sports Exerc 2017;49:396–402.

25. Schwanekamp JA, Lorts A, Vagnozzi RJ, Vanhouthe D, Molkentin JD. Deletion of perilostin protects against atherosclerosis in mice by altering inflammation and extracellular matrix remodeling. Arterioscler Thromb Vasc Biol 2016;36:60–8.

26. Tsouli SG, Kriotsis DN, Argyropoulou MI, Mikhalidis DP, Elias MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest 2005;35:236–44.

27. Tall AR, Small DM, Lees RS. Interaction of collagen with the lipids of tendon xanthoma. J Clin Invest 1978;62:836–46.

28. Vermeer BJ, Mattseen AA, van Gent CM, van Sabben RM, Emeis JJ. The lipid composition and localization of free and esterified cholesterol in different types of xanthomas. J Invest Dermatol 1982;78:305–8.

29. Bhattacharyya AK, Connor WE, Mausolf FA, Flatl AD. Turnover of xanthoma cholesterol in hyperlipoproteinaemia patients. J Lab Clin Med 1976;87:503–18.

30. Armstrong ML, Mathur SN, Sando GN, Megan MB. Lipid metabolism in xanthomatous skin of hypercholesterolemic rabbits. Am J Pathol 1986;125:339–48.

31. Sugiyama N, Marcovina S, Gown AM, Sefelt H, Joffe B, Chait A. Immunohistochemical distribution of lipoprotein epitopes in xanthoma from patients with familial hypercholesterolemia. Am J Pathol 1992;141:99–106.

32. Artieda M, Cenarro A, Junquera C, Lasierro P, Martinez-Lorenzo MJ, Pocovil M, et al. Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. FEBS Lett 2005;579:493–12.

33. Oosterveer DM, Versmissen J, Yasdananpanah M, van der Net JB, Defesche JC, Kastelein JJ, et al. 5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia. Atherosclerosis 2009;206:223–7.

34. Martin-Fuentes P, Civeira F, Solanas-Barca M, Garcia-Otin AL, Jarauta E, Cenarro A. Overexpression of the CXCL3 gene in response to oxidized low-density lipoprotein is associated with the presence of tendon xanthomas in familial hypercholesterolemia. Biochem Cell Biol 2009;87:493–5.

35. Hjuler Nielsen M, Irvine H, Vedel S, Raungaard B, Beck-Nielsen H. Elevated atherosclerosis-related gene expression, monocyte activation and microparticle-release are related to increased lipoprotein-associated oxidative stress in familial hypercholesterolemia. PLoS One 2015;10: e0121516.

36. Ronnemaa T, Juva K, Kulonen E. Effect of hyperlipidemic rat serum on the synthesis of collagen by chick embryo fibroblasts. Atherosclerosis 1975;21:315–24.

37. Nakano A, Kinoshita M, Okura R, Yasuda T, Abe M, Shiomi M. Pathogenesis of tendinous xanthoma: histopathological study of the extremities of Watanabe heritable hyperlipidemic rabbits. J Orthop Sci 2006;11:75–80.

38. Nunes RL, Bruschini H, Utsunomia K, Silveira MA, Teodoro WR. Epidemiology of tendon xanthomas in patients with hypercholesterolemia: a randomized, double-blind, active-controlled study. Curr Med Res Opin 2018;34:227–35.

39. Illingworth DR, Cope R, Bacon SP. Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin. South Med J 1990;83:1053–7.

40. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999;143:41–54.

41. Ballard KD, Taylor BA, Thompson PD. Statin-associated muscle injury. Eur J Prev Cardiol 2015;22:1161.

42. Teichtahl AJ, Brady SR, Urquhart DM, Wluka AE, Wang Y, Shaw JE, et al. Statins and tendinopathy: a systematic review. Med J Aust 2016;204:115–121 e1.

43. Deren ME, Klinge SA, Mukand NH, Mukand JA. Tendinopathy and tendon rupture associated with statins. JBJS Rev 2016;4.

44. Lin M, Dai H, Zhao S. Long-term atorvastatin-ezetimibe-probufol triple therapy for homozgyous familial hypercholesterolemia from early childhood. Cardiol Young 2016;26:197–201.

45. Shen L, Peng H, Xu D, Zhao S. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kinin 9 inhibitors. Pharmacol Res 2013;73:27–34.

46. Moroney PJ, Besse JL. Rejection of bilateral massive Achilles tendon xanthoma with reconstruction using a flexor hallucis longus tendon transfer and Bosworth turn-down flap: a case report and literature review. Foot Ankle Surg 2012;18:625–8.

47. Liddle AD, Rodriguez-Merchan EC. Platelet-rich plasma in the treatment of patellar tendinopathy: a systematic review. Am J Sports Med 2015;43:2583–90.

48. Andia I, Latorre PM, Gomez MC, Burgos-Alonso N, Abate M, Maffulli N. Platelet-rich plasma in the conservative treatment of painful tendinopathy: a systematic review and meta-analysis of controlled studies. Br Med Bull 2014;110:99–115.

49. Lee SY, Kim W, Lim C, Chung SG. Treatment of lateral epicondylitis by using allogeneic adipose-derived mesenchymal stem cells: a pilot study. Stem Cells 2015;33:2995–3005.

50. Usuelli FG, Massi M, Maccario C, Viganò M, Lanfranchi L, Alfieri Montrasio U, et al. Intratendinous adipose-derived stromal vascular fraction (SVF) injection provides a safe, efficacious treatment for Achilles tendinitis: results of a randomized controlled clinical trial at a 6-month follow-up. Knee Surg Sports Traumatol Arthrosc 2018 Jul;26(7):2000–10.

51. Imam MA, Holton J, Horriat S, Negida AS, Grubhofer F, Gupta R, et al. A systematic review of the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology. Sicot J 2017;3:58.

52. Mathiak G, Wening JV, Mathiak M, Neville LF, Jungbluth K. Pathogenesis, detection and treatment of Achilles tendon xanthoma: a histopathological study. Histol Histopathol 2012;27:745–52.

53. Rechardt M, Shiri R, Lindholm H, Karppinen J, Vilkarri-Juntura E. Associations of metabolic factors and adipokines with pain in incipient upper extremity soft tissue disorders: a cross-sectional study. BMJ Open 2013;3:e003036.
[60] Abate M, Schiavone C, Di Carlo L, Salini V. Prevalence of and risk factors for asymptomatic rotator cuff tears in postmenopausal women. Menopause 2014;21:275–80.

[61] Oliva F, Osti L, Padulo J, Maffulli N. Epidemiology of the rotator cuff tears: a new incidence related to thyroid disease. Muscles Ligaments Tendons J 2014;4:309–14.

[62] Djerbi I, Chammas M, Mirous MP, Lazerges C, Coulet B. Impact of cardiovascular risk factor on the prevalence and severity of symptomatic full-thickness rotator cuff tears. Orthop Traumatol Surg Res 2015;101:S269–73.

[63] Kim JM, Kim MW, Do HJ. Influence of hyperlipidemia on the treatment of supraspinatus tendinopathy with or without tear. Ann Rehabil Med 2016;40:463–9.

[64] Abate M, Di Carlo L, Salini V, Schiavone C. Risk factors associated to bilateral rotator cuff tears. Orthop Traumatol Surg Res 2017;103:841–5.

[65] Applegate KA, Thiese MS, Merryweather AS, Kapellusch J, Drury DL, Wood E, et al. Association between cardiovascular disease risk factors and rotator cuff tendinopathy: a cross-sectional study. J Occup Environ Med 2017;59:154–60.

[66] Juge PA, Berard L, Kotti S, Doursounian L, Sautet A, Simon T, et al. Cardiometabolic risk factors in primary centred and rotator cuff-related shoulder osteoarthritis: a comparative study. RMD Open 2017;3:e000429.